Recent Quotes (30 days)

You have no recent quotes
chg | %

ProMetic Life Sciences Inc.  

(Public, TSE:PLI)   Watch this stock  
Find more results for PLI
3.00
+0.06 (2.04%)
May 20 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 2.92 - 3.05
52 week 1.39 - 3.62
Open 2.96
Vol / Avg. 1.30M/1.26M
Mkt cap 1.71B
P/E     -
Div/yield     -
EPS -0.08
Shares 582.15M
Beta 1.70
Inst. own     -
Aug 11, 2016
Q2 2016 ProMetic Life Sciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 10, 2016
ProMetic Life Sciences Inc at Jefferies Healthcare Conference - 1:00PM EDT - Add to calendar
May 25, 2016
ProMetic Life Sciences Inc at UBS Global Healthcare Conference - 8:30AM EDT - Add to calendar
May 12, 2016
Q1 2016 ProMetic Life Sciences Inc Earnings Release
May 11, 2016
ProMetic Life Sciences Inc Annual Shareholders Meeting
Mar 31, 2016
Q4 2015 ProMetic Life Sciences Inc Earnings Call and Phase II/III Clinical Trial Results
Mar 30, 2016
Q4 2015 ProMetic Life Sciences Inc Earnings Release
  

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -342.22% -231.45%
Operating margin -340.01% -243.29%
EBITD margin - -195.94%
Return on average assets -32.54% -27.12%
Return on average equity -56.70% -55.60%
Employees 276 -
CDP Score - -

Address

440 Armand-Frappier Blvd Suite 300
LAVAL, QC H7V 4B4
Canada
+1-450-7810115 (Phone)
+1-450-7814477 (Fax)

Website links

Description

ProMetic Life Sciences Inc. (ProMetic) is a Canada-based biopharmaceutical company. The Company offers solutions in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens. The Company operates through two segments: Therapeutics and Protein Technology. Therapeutics segment is a small molecule drug discovery business. It has lead compounds, namely PBI-4050 indicated for the treatment of fibrosis in patients with chronic kidney diseases and certain cancers, and the side effects associated with chemotherapy. Protein Technology segment contains the financial information of the activities, including BioTherapeutics, Bioseparation and Prion Capture/Pathogen Removal.

Officers and directors

Simon Geoffrey Best Independent Chairman of the Board
Age: 58
Pierre Laurin Ph.D. President, Chief Executive Officer, Director
Age: 75
Gregory L. Weaver Chief Financial Officer
Age: 59
Steve J. Burton Chief Executive Officer of ProMetic BioSciences Ltd.
Age: 63
Bruce Pritchard Chief Operating Officer
Patrick Sartore General Counsel, Corporate Secretary
John Moran M.D. Chief Medical Officer, Director
Age: 69
Dwun-Hou Chen Ph.D. Senior Vice President, Product and Asia Pacific Development of ProMetic BioTherapeutics, Inc.
Stefan Clulow Director
Age: 44
Charles Kenworthy Director
Age: 57